Edwards Lifesciences Corporation

Edwards Lifesciences Beats on EPS, Stock Down 0.97%

Edwards Lifesciences reported better-than-expected earnings per share, which indicates some resilience in their business. However, the stock reacted negatively, declining by nearly 1%. This could suggest that investors were expecting more clarity or stronger performance in other areas, particularly revenue, which was not disclosed.